Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Scarr, Elizabeth ^a   Money, Tammie T ^a   Pavey, Geoffrey ^a   Neo, Jaclyn ^a   Dean, Brian ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; TRITIUM;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CAUDATE NUCLEUS; CONTROLLED STUDY; FEMALE; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; PUTAMEN; SAMPLE SIZE; SCHIZOPHRENIA; SUICIDE; WESTERN BLOTTING; CAUSE OF DEATH; HUMAN TISSUE; RADIOASSAY; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR OCCUPANCY;

ADULT; BIPOLAR DISORDER; BRAIN; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, OPIOID, MU; SCHIZOPHRENIA; SUICIDE;

EID: 84865322124     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-126     Document Type: Article

References (51)

1. Maris RW. Suicide. Lancet 2002, 360:319-326. 10.1016/S0140-6736(02)09556-9, 12147388.
2. Mortensen PB, Agerbo E, Erikson T, Qin P, Westergaard-Nielsen N. Psychiatric illness and risk factors for suicide in Denmark. Lancet 2000, 355:9-12. 10.1016/S0140-6736(99)06376-X, 10615884.
3. Chen EY, Chan WS, Wong PW, Chan SS, Chan CL, Law YW, Beh PS, Chan KK, Cheng JW, Liu KY, et al. Suicide in Hong Kong: a case-control psychological autopsy study. Psychol Med 2006, 36:815-825. 10.1017/S0033291706007240, 16704748.
4. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003, 33:395-405. 10.1017/S0033291702006943, 12701661.
5. Li Z, Page A, Martin G, Taylor R. Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. Soc Sci Med 2011, 72:608-616. 10.1016/j.socscimed.2010.11.008, 21211874.
6. Kamali M, Oquendo MA, Mann JJ. Understanding the neurobiology of suicidal behavior. Depress Anxiety 2001, 14:164-176. 10.1002/da.1062, 11747126.
7. Pandey GN, Dwivedi Y, Pandey SC, Conley RR, Roberts RC, Tamminga CA. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997, 228:111-114. 10.1016/S0304-3940(97)00378-9, 9209111.
8. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995, 675:157-164. 10.1016/0006-8993(95)00057-W, 7796124.
9. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006, 63:1199-1208. 10.1001/archpsyc.63.11.1199, 17088500.
10. Peckys D, Hurd YL. Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res Bull 2001, 55:619-624. 10.1016/S0361-9230(01)00525-1, 11576758.
11. Sher L, Stanley BH. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch Suicide Res 2008, 12:299-308. 10.1080/13811110802324748, 18828033.
12. Gross-Isseroff R, Dillon KA, Israeli M, Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 1990, 530:312-316. 10.1016/0006-8993(90)91301-V, 2176118.
13. Gabilondo AM, Meana JJ, Garcia-Sevilla JA. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res 1995, 682:245-250. 10.1016/0006-8993(95)00333-L, 7552322.
14. Zalsman G, Molcho A, Huang Y, Dwork A, Li S, Mann JJ. Postmortem μ-opioid receptor binding in suicide victims and controls. J Neural Transm 2005, 112:949-954. 10.1007/s00702-004-0239-3, 15937639.
15. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the diagnosis of schizophrenia after death using DSM- IV: a victorian experience. Aust N Z J Psychiatry 1998, 32:73-76. 10.3109/00048679809062709, 9565186.
16. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Copolov D. Diagnostic instrument for brain studies 1999, Melbourne: Mental Health Research Institute.
17. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, Washington, D.C: American Psychiatric Association, American Psychiatric Association.
18. Hill C, Keks N, Roberts S, Opeskin K, Dean B, MacKinnon A, Copolov D. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry 1996, 153:533-537.
19. Remington GJ. Antipsychotics (Neuroleptics). Clincal handbook of psychotropic drugs 1999, 55-84. Seattle; Toronto: Göttingen; Bern: Hogrefe & Huber, Bezchlibnyk-Butler KZ, Jeffries JJ, 9.
20. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M, Giaccone G, Krebs B, et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 2007, 66:35-46. 10.1097/nen.0b013e31802c3e7d, 17204935.
21. Dean B, Pavey G, Chai SW, Mendelsohn FAO. The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. The use of CNS autopsy tissue in psychiatric research: a practical guide 1999, 67-83. Sydney: Gordon & Breach Science Publishers, Dean B, Hyde TM, Kleinman JE.
22. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, Lees AJ, Marsden CD. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995, 28:311-318.
23. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, Tamminga CA. Human postmortem tissue: what quality markers matter?. Brain Res 2006, 1123:1-11. 10.1016/j.brainres.2006.09.025, 1995236, 17045977.
24. Rodbard D. Mathematics and statistics of ligand assays. Ligand Assay: analysis of international developments on isotopic and nonisotopic immunoassay 1981, 55-101. New York: Masson, Langan J, Clapp JJ, 1.
25. Dean B, Pavey G, Opeskin K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology 1997, 36:779-786. 10.1016/S0028-3908(97)00067-1, 9225305.
26. Pavey GM, Copolov DL, Dean B. High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding. J Neurosci Methods 2002, 116:157-163. 10.1016/S0165-0270(02)00036-5, 12044665.
27. Gabilondo AM, Meana JJ, Barturen F, Sastre M, Garcia-Sevilla JA. mu-opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology (Berl) 1994, 115:135-140.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354. 10.1073/pnas.76.9.4350, 411572, 388439.
29. Dean B, Gray L, Keriakous D, Scarr E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus & Related Systems 2004, 2:287-295.
30. Gliner JA, Morgan GA, Harmon RJ. Basic associated designs: analysis and interpretation. J Am Acad Child Adolesc Psychiatry 2002, 41:1256-1258. 10.1097/00004583-200210000-00017, 12364849.
31. Hassan AHS, Almeida OFX, Gramsch C, Herz A. Immunocytochemical demonstration of opioid receptors in selected rat brain areas and neuroblastoma + glioma hybrid (NG108-15) cells using a monoclonal anti-idiotypic antibody. Neuroscience 1989, 32:269-278. 10.1016/0306-4522(89)90126-7, 2555734.
32. Svingos AL, Colago EE, Pickel VM. Vesicular acetylcholine transporter in the rat nucleus accumbens shell: subcellular distribution and association with mu-opioid receptors. Synapse 2001, 40:184-192. 10.1002/syn.1041, 11304756.
33. Phansuwan-Pujito P, Ebadi M, Govitrapong P. Immunocytochemical characterization of delta-opioid and mu-opioid receptor protein in the bovine pineal gland. Cells Tissues Organs 2006, 182:48-56. 10.1159/000091718, 16651829.
34. de Gandarias JM, Acebes I, Echevarria E, Vegas L, Abecia LC, Casis L. Lithium alters mu-opioid receptor expression in the rat brain. Neurosci Lett 2000, 279:9-12. 10.1016/S0304-3940(99)00944-1, 10670775.
35. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human [mu] opioid receptor gene, Oprm. Neuroscience 2005, 133:209-220. 10.1016/j.neuroscience.2004.12.033, 15893644.
36. Morley JE, Flood JF, Silver AJ. Opioid peptides and aging. Ann N Y Acad Sci 1990, 579:123-132. 10.1111/j.1749-6632.1990.tb48355.x, 2159741.
37. Washington LL, Gibson SJ, Helme RD. Age-related differences in the endogenous analgesic response to repeated cold water immersion in human volunteers. Pain 2000, 89:89-96. 10.1016/S0304-3959(00)00352-3, 11113297.
38. Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M. Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand Suppl 1981, 291:20-28.
39. Reisine TD, Rossor M, Spokes E, Iversen LL, Yamamura HI. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. Adv Biochem Psychopharmacol 1980, 21:443-450.
40. van der Werf JF, Sebens JB, Vaalburg W, Korf J. In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol 1983, 87:259-270. 10.1016/0014-2999(83)90336-9, 6404643.
41. Kohler C, Hall H, Ogren SO, Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 1985, 34:2251-2259. 10.1016/0006-2952(85)90778-6, 4015674.
42. Love TM, Stohler CS, Zubieta JK. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry 2009, 66:1124-1134. 10.1001/archgenpsychiatry.2009.134, 3085183, 19805703.
43. Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton P, Currier D, Dougherty DM, Haghighi F, Hodge SE, et al. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009, 65:556-563. 10.1016/j.biopsych.2008.11.021, 3271953, 19201395.
44. Fichna J, Janecka A, Costentin J, Do Rego JC. The Endomorphin System and Its Evolving Neurophysiological Role. Pharmacol Rev 2007, 59:88-123. 10.1124/pr.59.1.3, 17329549.
45. Bower CM, Hyde TM, Zaka M, Hamid EH, Baca SM, Egan MF. Decreased mu-opioid receptor binding in the globus pallidus of rats treated with chronic haloperidol. Psychopharmacology (Berl) 2000, 150:260-263.
46. Sasaki T, Kennedy JL, Nobrega JN. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements. Psychopharmacology (Berl) 1996, 128:97-104.
47. Delay-Goyet P, Zajac JM, Roques BP. Effects of repeated treatment with haloperidol on rat striatal neutral endopeptidase, and on mu- and delta-opioid binding sites: comparison with chronic morphine and chronic kelatorphan. Neurosci Lett 1989, 103:197-202. 10.1016/0304-3940(89)90575-2, 2549472.
48. Zhang SP, Connell TA, Price T, Simpson GM, Zhou LW, Weiss B. Continuous infusion of clozapine increases mu and delta opioid receptors and proenkephalin mRNA in mouse brain. Biol Psychiatry 1995, 37:496-503. 10.1016/0006-3223(94)00185-6, 7619972.
49. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005, 62:247-253. 10.1001/archpsyc.62.3.247, 15753237.
50. Pompili M, Girardi P, Ruberto A, Tatarelli R. Toward a new prevention of suicide in schizophrenia. World J Biol Psychiatry 2004, 5:201-210. 10.1080/15622970410029934, 15543514.
51. Welch EB, Thompson DF. Opiate antagonists for the treatment of schizophrenia. J Clin Pharm Ther 1994, 19:279-283. 10.1111/j.1365-2710.1994.tb00814.x, 7806598.